Download PDF
Z Gastroenterol 2011; 49(11): 1463-1469
DOI: 10.1055/s-0031-1281582
Originalarbeit

© Georg Thieme Verlag KG Stuttgart · New York

Quantification of HBsAg and HBV-DNA during Therapy with Peginterferon alpha-2b plus Lamivudine and Peginterferon alpha-2b Alone in a German Chronic Hepatitis B Cohort

Verlauf des quantitativen HBsAg und der HBV-DNA während der Therapie mit Peginterferon alpha-2b plus Lamivudin oder Peginterferon alpha-2b in einer deutschen Hepatitis-B-KohorteJ. Wiegand1 , O. Brosteanu2 , U. Kullig3 , M. Wiese4 , 5 , F. Berr6 , M. Maier7 , H. L. Tillmann1 , 8 , I. Schiefke5 , 9
  • 1Department of Medicine, Dermatology and Neurology, Division of Gastroenterology & Rheumatology, University of Leipzig, Leipzig, Germany
  • 2Clinical Trial Center, University of Leipzig, Leipzig, Germany
  • 3Department of Internal Medicine III, Klinikum Friedrichstadt, Dresden, Germany
  • 4Center for Digestion and Metabolism, Leipzig, Germany
  • 5Department of Gastroenterology and Hepatology, St George Hospital, Leipzig, Germany
  • 6Department of Internal Medicine I, Landeskrankenhaus Salzburg, Salzburg, Austria
  • 7Institute of Virology, University of Leipzig, Leipzig, Germany
  • 8Duke Clinical Research Institute, Duke University Medical Center, Durham, USA
  • 9Center for Gastroenterology and Hepatology, Leipzig, Germany
Further Information

Publication History

manuscript received: 26.2.2011

manuscript accepted: 9.6.2011

Publication Date:
08 November 2011 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Hintergrund: Peginterferon alpha-2b (PEG-IFNa2b) und Lamivudin sind effektive Behandlungsoptionen bei einer chronischer Hepatitis-B-Infektion. Es gab Hinweise, dass die Kombinationstherapie von PEG-IFNα-2b und Lamivudin im Vergleich zur Monotherapie eine höhere Rate an HBeAg-Serokonversion induziert sowie eine stärkere Suppression der HBV-DNA- und der HBsAg-Produktion erreichen kann. Patienten und Methodik: 59 Patienten mit chronischer Hepatitis B wurden in die Studie eingeschlossen. Es erfolgte die Randomisation in eine 9-monatige Therapie mit PEG-IFNα-2b 1,5 µg/kg o. i. w. (n = 27) oder PEG-IFNα-2b plus Lamivudin 100 mg (n = 32). Die Nachbeobachtungszeit betrug 24 Wochen. Das primäre Zielkriterium war der Verlust der HBV-DNA 24 Wochen nach Ende der Therapie. HBV-DNA (PCR) und HBsAg (Axsym, Abbott) wurden zu Beginn, am Ende der Therapie und am Ende der Nachbeobachtungszeit quantitativ bestimmt, während die HBeAg (Axsym, Abbott) Bestimmung zu den gleichen Zeitpunkt qualitativ erfolgte. Die Bestimmung der HBV-Genotypen erfolgte mit dem Innolipa Assay (Innogenetics). Resultate: Es wurden lediglich 32 Patienten in die Gruppe der Kombinationstherapie und 27 Patienten in die Gruppe der Monotherapie randomisiert. Der Abfall der HBV-DNA (4,60 log vs. 2,41 log; p = 0,003) war signifikant stärker unter Kombinationstherapie. Der Anteil der Patienten mit ALT-Normalisierung, viraler Suppression (HBV-DNA < 400 copies/mL) und einer HBeAg Serokonversion war jedoch ohne Unterschied zwischen den Behandlungsgruppen. Der HBV-Genotyp hatte keinen Einfluss auf die Zielparameter. In einer Post-hoc-Analyse wurden bei 29 Patienten zusätzlich HBsAg-Spiegel bestimmt. Hierbei zeigte die Kombinationstherapie sowohl während (– 0,7 ± 1,17 log IU/mL vs. –0,26 ± 0,61 log IU/mL; p = 0,35) als auch nach der Behandlung (– 0,68 ± 1,29 log IU/mL vs. – 0,24 ± 0,56 log IU/mL; p = 0,82) einen stärkeren, aber nicht signifikanten Abfall des HBsAg. Zwei von 3 Patienten mit 2 log HBsAg-Abfall unter 100 IU/mL erreichten in der Langzeitnachbeobachtung einen HBsAg-Verlust. Diskussion: Aufgrund geringer Rekrutierungszahlen erreichte die Studie nicht den primären Studienendpunkt. Jedoch zeigte sich in einer Post-hoc-Analyse ein mehr als 2-fach stärkerer HBsAg-Abfall in der Kombinationstherapie, wobei nach Absetzen des Lamivudins kein Wiederanstieg des HBsAg beobachtet wurde. Dieses Ergebnis kann auf einen Nutzen zukünftiger Kombinationstherapien hinweisen, bei denen die Nucleos(t)idtherapie fortgeführt wird.

Abstract

Background: Peginterferon alpha-2b (PEG-IFNa2b) and lamivudine are efficient treatment options for chronic hepatitis B virus (HBV) infection. We assumed that a combination therapy of PEG-IFNα-2b plus lamivudine will be more effective than PEG-IFNα-2b alone concerning loss of HBV-DNA, HBeAg seroconversion, and HBsAg reduction. Patients and Methods: Patients with chronic hepatitis B were randomised to nine months treatment with PEG-IFNα-2b 1.5 µg/kg o. i. w. or PEG- IFNα-2b plus lamivudine 100 mg/d. The study was designed with 60 patients per treatment arm. The primary endpoint was defined as loss of HBV-DNA (< 400 copies/mL) 24 weeks after the end of therapy. HBV-DNA (PCR), HBsAg (Architect, Abbott), and HBeAg (Axsym, Abbott) were determined prior to and at the end of treatment as well as at follow-up. HBV-genotypes were determined by Innolipa (Innogenetics). Results: Only 32 patients were randomised to combination therapy and 27 individuals to monotherapy due to low recruitment rates. On treatment reduction of HBV-DNA was significantly higher during combination therapy compared to PEG-IFNa-2b monotherapy (– 4.60 ± 2.71 vs. – 2.41 ± 2.17 log; p = 0.003). However, there was no difference in the number of cases achieving HBV-DNA < 400 copies/mL, ALT normalisation, or HBeAg seroconversion at follow-up. None of the parameters was significantly related to HBV-genotypes. In a post-hoc analysis serum HBsAg levels were analysed as an additional prognostic parameter for treatment response (n = 29). Combination therapy showed a stronger, but not significant HBsAg decline during (– 0.7 ± 1.17 log IU/mL vs. – 0.26 ± 0.61 log IU/mL; p = 0.35) and after therapy (– 0.68 ± 1.29 log IU/mL vs. – 0.24 ± 0.56 log IU/mL; p = 0.82). Two of three cases with a 2-log HBsAg decline to HBsAg levels < 100 IU/mL eliminated HBsAg during long-term follow-up. Conclusion: The study was underpowered with respect to the primary endpoint due to low recruitment rates. However, in the post-hoc analysis HBsAg decline was over two-fold stronger at the end of treatment and follow-up after combination therapy and did not rebound after lamivudine withdrawal. These results may indicate the usefulness of future combination therapies without discontinuation of nucleos(t)ide analogues.

Schlüsselwörter

chronische Hepatitis B - Virushepatitis - Leber - Therapie - HBsAg quantitativ

Key words

chronic hepatitis B - viral hepatitis - liver - therapy - HBsAg quantitative

References

  • 1 Cornberg M, Protzer U, Dollinger M M et al. Prophylaxis, diagnosis and therapy of hepatitis-B-virus-(HBV-) infection: upgrade of the guideline, AWMF-Register 021 / 011.  Z Gastroenterol. 2007;  45 525-574
    Google Scholar
  • 2 European Association for the Study of the Liver . EASL Clinical Practice Guidelines: Management of chronic hepatitis.  B. J Hepatol. 2009;  50 227-242
    Google Scholar
  • 3 Niederau C. Epidemiology of hepatitis B in Germany.  Med Klin. 2007;  102 351-357
    Google Scholar
  • 4 Lutgehetmann M, Meyer F, Volz T et al. Knowledge about HBV, prevention behaviour and treatment adherence of patients with chronic hepatitis B in a large referral centre in Germany.  Z Gastroenterol. 2010;  48 1126-1132
    Google Scholar
  • 5 Wormann T, Prufer-Kramer L, Kramer A. Serological and sociodemographic differences in HBV-patients with and without migration background.  Z Gastroenterol. 2010;  48 533-541
    Google Scholar
  • 6 Lescrauwaet B, Gwed S, Ponsonnet D et al. A cross-sectional analysis of chronic hepatitis B patient characteristics and clinical management patterns in Germany, Poland, Romania, and Turkey.  J Hepatol. 2010;  52 (S1) S279
    Google Scholar
  • 7 Wiegand J, Wedemeyer H, Finger A et al. A decline in hepatitis B virus surface antigen (HBsAg) predicts clearance, but does not correlate with quantitative HBeAg or HBV DNA levels.  Antivir Ther. 2008;  13 547-554
    Google Scholar
  • 8 Gish R G, Chang T T, Lai C L et al. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B.  J Viral Hepat. 2010;  17 16-22
    Google Scholar
  • 9 Heathcote E J, Marcellin P, Buti M et al. Three-year efficacy and safety of tenofovir disoproxil fumerate treatment for chronic hepatitis B.  Gastroenterology. 2011;  140 132-143
    Google Scholar
  • 10 Marcellin P, Bonino F, Lau G K et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a.  Gastroenterology. 2009;  136 2169-2179
    Google Scholar
  • 11 Marcellin P, Piratvisuth T, Brunetto M et al. Increasing rates of HBsAg clearance and seroconversion in patients with HBeAg-negative disease treated with peginterferon alpha-2a + /– lamivudine: results of 5-year post-treatment follow up.  J Hepatol. 2009;  50 S336
    Google Scholar
  • 12 Flink H J, Zonneveld van M, Hansen B E et al. Treatment with Peg-Interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.  Am J Gastroenterol. 2006;  101 297-303
    Google Scholar
  • 13 Wiegand J, Hasenclever D, Tillmann H L. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence.  Antivir Ther. 2008;  13 211-220
    Google Scholar
  • 14 Buster E H, Hansen B E, Lau G K et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alpha.  Gastroenterology. 2009;  137 2002-2009
    Google Scholar
  • 15 Brunetto M R, Moriconi F, Bonino F et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alpha-2a in HBeAg-negative chronic hepatitis B.  Hepatology. 2009;  49 1141-1150
    Google Scholar
  • 16 Moucari R, Mackiewicz V, Lada O et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alpha-2a in HBeAg-negative patients.  Hepatology. 2009;  49 1151-1157
    Google Scholar
  • 17 Rijckborst V, Hansen B E, Cakaloglu Y et al. Early on-treatment prediction of response to peginterferon alpha-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.  Hepatology. 2010;  52 454-461
    Google Scholar
  • 18 Manesis E K, Hadziyannis E S, Angelopoulou O P et al. Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels.  Antivir Ther. 2007;  12 73-82
    Google Scholar
  • 19 Ma H, Yang R F, Wei L. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alpha-2b in HBeAg-positive patients.  J Gastroenterol Hepatol. 2010;  25 1498-1506
    Google Scholar
  • 20 Sonneveld M J, Rijckborst V, Boucher C A et al. Prediction of sustained response to peginterferon alpha-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.  Hepatology. 2010;  52 449-454
    Google Scholar
  • 21 Moucari R, Korevaar A, Lada O et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study.  J Hepatol. 2009;  50 1084-1092
    Google Scholar
  • 22 Wong V W, Wong G L, Yan K K et al. Durability of peginterferon alpha-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.  Hepatology. 2010;  51 1945-1953
    Google Scholar
  • 23 Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis.  J Hepatol. 1995;  22 696-699
    Google Scholar
  • 24 Janssen H L, Zonneveld van M, Senturk H et al. Pegylated interferon alpha-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.  Lancet. 2005;  365 (9454) 123-129
    Google Scholar
  • 25 Chan H L, Leung N W, Hui A Y et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone.  Ann Intern Med. 2005;  142 240-250
    Google Scholar
  • 26 Sung J J, Wong M L, Bowden S et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy.  Gastroenterology. 2005;  128 1890-1897
    Google Scholar
  • 27 Wursthorn K, Lutgehetmann M, Dandri M et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.  Hepatology. 2006;  44 675-684
    Google Scholar
  • 28 Chan H L, Wong V W, Tse A M et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.  Clin Gastroenterol Hepatol. 2007;  5 1462-1468
    Google Scholar
  • 29 Thompson A J, Nguyen T, Iser D et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: Disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers.  Hepatology. 2010;  51 1933-1944
    Google Scholar
  • 30 Tillmann H L, Wiegand J, Glomb I et al. Diagnostic algorithm for chronic hepatitis C virus infection: role of the new HCV-core antigen assay.  Z Gastroenterol. 2005;  43 11-16
    Google Scholar
  • 31 Pradat P, Maynard M, Buti M et al. The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated interferon/ribavirin treatment.  J Med Virol. 2004;  73 392-396
    Google Scholar
  • 32 Mederacke I, Wedemeyer H, Ciesek S et al. Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay.  J Clin Virol. 2009;  46 210-215
    Google Scholar
  • 33 Lok A S, McMahon B J. Chronic hepatitis B: update 2009.  Hepatology. 2009;  50 661-662
    Google Scholar
  • 34 Berg T, Benhamou Y, Calleja J L et al. A survey of chronic hepatitis B patient management practices in the European Union.  J Viral Hepat. 2010;  17 624-630
    Google Scholar
  • 35 Deterding K, Constantinescu I, Nedelcu F D et al. Prevalence of HBV genotypes in Central and Eastern Europe.  J Med Virol. 2008;  80 1707-1711
    Google Scholar
  • 36 Tangkijvanich P, Komolmit P, Mahachai V et al. Comparison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-alpha-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B.  Hepatol Res. 2010;  40 269-277
    Google Scholar

Prof. Dr. Ingolf Schiefke

Department of Gastroenterology and Hepatology, St. George Hospital

Delitzscher Str. 141

04129 Leipzig

Germany

Phone:  ++ 49/3 41/9 09 26 26

Fax:  ++ 49/3 41/9 09 26 73

Email: ingolf.schiefke@sanktgeorg.de

      >